ElectroCore, Inc. 10-Q Summary
Business Context and Reporting Period
ElectroCore is a commercial-stage bioelectronic medicine and wellness company using non-invasive vagus nerve stimulation technology. Its principal products are prescription gammaCore devices, Truvaga wellness products, and TAC-STIM human-performance products. The unaudited report covers the three months ended March 31, 2024, compared with the same period in 2023. The company paused operations in Germany, with European sales managed by its U.K. subsidiary.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $5.443 million | $2.780 million | +96% |
| Gross profit | $4.555 million | $2.322 million | +$2.233 million |
| Gross margin | 84% | 84% | Unchanged |
| Operating expenses | $8.404 million | $8.519 million | -$0.115 million |
| Loss from operations | $(3.849) million | $(6.197) million | Improved by $2.348 million |
| Net loss | $(3.506) million | $(5.867) million | Improved by $2.361 million |
| Basic and diluted loss per share | $(0.53) | $(1.24) | Improved |
| Net cash used in operating activities | $(2.558) million | $(5.860) million | Improved by $3.302 million |
Revenue concentration remained significant: VA/DoD represented 71.2% of Q1 2024 revenue, compared with 61.3% in Q1 2023. TAC-STIM represented 5.5% and the U.K. National Health Service represented 6.3% of Q1 2024 revenue. Cash and cash equivalents were $7.849 million at March 31, 2024, plus $0.250 million of restricted cash, for total cash, cash equivalents and restricted cash of $8.099 million. This compares with $10.581 million at December 31, 2023.
Total assets were $13.890 million and total liabilities were $9.394 million at March 31, 2024. The company reported no senior debt; liabilities primarily consisted of accounts payable, accrued expenses, and operating lease liabilities. Operating lease liabilities totaled $1.660 million, following a lease extension and expansion agreement. Stockholders’ equity declined to $4.496 million from $7.442 million at year-end 2023, principally due to the quarterly net loss.
Material Changes Versus the Prior Comparable Period
- Net sales increased $2.663 million, driven by higher sales of prescription gammaCore devices and increased Truvaga and TAC-STIM revenue.
- VA/DoD gammaCore revenue increased to $3.875 million from $1.705 million.
- Truvaga revenue increased to $385,000 from $147,000, while TAC-STIM revenue increased to $301,000 from $88,000.
- Research and development expense decreased to $399,000 from $1.809 million because investment in next-generation smartphone-integrated and smartphone-connected therapies was reduced.
- Selling, general and administrative expense increased 19% to $8.005 million, primarily due to higher variable sales and marketing costs.
- Operating cash burn decreased substantially, although cash remained negative and the company continued to incur losses.
- The company launched Truvaga Plus in April 2024, after the reporting period.
- The Rockaway, New Jersey lease was extended for an additional 10 years, with expansion from 13,643 to 22,557 square feet. The expanded space is scheduled to commence June 1, 2024.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects negative operating cash flow and continued net losses during 2024. It plans targeted investments in sales and marketing and in the next generation of its therapy delivery platform.
- The company stated that substantial doubt exists about its ability to continue as a going concern within one year after issuance of the financial statements. Future liquidity depends substantially on commercial success and expense control; the company may need to reduce or curtail activities or potentially cease operations.
- The VA/DoD Federal Supply Schedule contract was extended from January 15, 2024 to March 14, 2024 and then to June 14, 2024 while the company’s replacement application is reviewed. Failure to obtain a replacement could limit or eliminate certain government-channel sales.
- The company received approximately $7.5 million of net proceeds from an August 2023 registered direct offering and concurrent private placements. No financing cash was raised during Q1 2024.
- NHS Supply Chain intends to continue including gammaCore in its framework agreement from March 2024 through March 2026, subject to the disclosed terms. NICE guidance or pricing changes could adversely affect U.K. sales.
- A stockholder securities litigation appeal remains pending in the Third Circuit. The company has not accrued a loss because the probability and amount of any loss cannot reasonably be determined; substantial defense costs, judgment, or settlement remain possible.
- Disclosure controls and procedures were determined to be ineffective because of a material weakness involving vendor-payment and vendor-information controls. Management began remediation in Q1 2024. No financial-statement misstatement was identified.
- Interest and other income included approximately $123,000 of recovery proceeds related to a 2023 casualty loss. The company also received $122,000 from the sale of New Jersey state net operating losses.
- The company had 924,000 stock purchase warrants outstanding with a weighted-average exercise price of $4.54, plus 613,314 pre-funded warrants that had not been exercised as of March 31, 2024.
Most Important Facts for Investors to Verify
- Whether the VA/DoD replacement FSS contract was obtained after the June 14, 2024 extension and the effect on government-channel revenue.
- Whether cash balances and operating cash flow are sufficient to fund operations without additional equity or other financing.
- Whether the company can sustain Q1’s revenue growth while reducing losses and maintaining its 84% gross margin.
- Progress in remediating the vendor-payment internal-control material weakness.
- The status and potential financial exposure of the stockholder litigation appeal.
- Commercial adoption of Truvaga Plus, TAC-STIM, and gammaCore outside the concentrated VA/DoD and NHS channels.